These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29525646)

  • 1. Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.
    Ohiri JC; McNally EM
    Heart Fail Clin; 2018 Apr; 14(2):179-188. PubMed ID: 29525646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias.
    Ryan T; Roberts JD
    Card Electrophysiol Clin; 2023 Sep; 15(3):261-271. PubMed ID: 37558297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Myoediting Attenuates Cardiac Abnormalities in Human and Mouse Models of Duchenne Muscular Dystrophy.
    Atmanli A; Chai AC; Cui M; Wang Z; Nishiyama T; Bassel-Duby R; Olson EN
    Circ Res; 2021 Sep; 129(6):602-616. PubMed ID: 34372664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
    Hwang J; Yokota T
    Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.
    Fayssoil A; Nardi O; Orlikowski D; Annane D
    Heart Fail Rev; 2010 Jan; 15(1):103-7. PubMed ID: 19943106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic correction strategies for Duchenne Muscular Dystrophy and their impact on the heart.
    Johnston JR; McNally EM
    Prog Pediatr Cardiol; 2021 Dec; 63():. PubMed ID: 34898968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases.
    Chiu W; Hsun YH; Chang KJ; Yarmishyn AA; Hsiao YJ; Chien Y; Chien CS; Ma C; Yang YP; Tsai PH; Chiou SH; Lin TY; Cheng HM
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne muscular dystrophy: genome editing gives new hope for treatment.
    Crispi V; Matsakas A
    Postgrad Med J; 2018 May; 94(1111):296-304. PubMed ID: 29386334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in gene therapy of dystrophic heart disease.
    Lai Y; Duan D
    Gene Ther; 2012 Jun; 19(6):678-85. PubMed ID: 22318092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for heart failure and cardiomyopathies.
    Argirò A; Ding J; Adler E
    Rev Esp Cardiol (Engl Ed); 2023 Dec; 76(12):1042-1054. PubMed ID: 37506969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dystrophin-Deficient Cardiomyopathy.
    Kamdar F; Garry DJ
    J Am Coll Cardiol; 2016 May; 67(21):2533-46. PubMed ID: 27230049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of
    Brescia M; Janssen JM; Liu J; Gonçalves MAFV
    Cells; 2020 Apr; 9(4):. PubMed ID: 32252479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy.
    Li G; Jin M; Li Z; Xiao Q; Lin J; Yang D; Liu Y; Wang X; Xie L; Ying W; Wang H; Zuo E; Shi L; Wang N; Chen W; Xu C; Yang H
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36512423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.
    Bostick B; Shin JH; Yue Y; Wasala NB; Lai Y; Duan D
    J Mol Cell Cardiol; 2012 Aug; 53(2):217-22. PubMed ID: 22587991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.
    Prondzynski M; Mearini G; Carrier L
    Pflugers Arch; 2019 May; 471(5):807-815. PubMed ID: 29971600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making gene editing a therapeutic reality.
    Conboy I; Murthy N; Etienne J; Robinson Z
    F1000Res; 2018; 7():. PubMed ID: 30613384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the correction of muscular dystrophy by gene editing.
    Olson EN
    Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34074727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.